

## We Are Recording!



Personal information in this initiative is collected under s.26(c) and 26(d)(ii) of the Freedom of Information and Protection of Privacy Act. The information is being collected in order to facilitate learning as part of the Learning about Opioid Use Disorder in the Emergency Department (LOUD in the ED) initiative. This session is being recorded and will be shared on the BCPSQC website. Breakout room discussions will not be recorded. We ask that you refrain from identifying patients, specific team members or offering any other personal information. If you have further questions, please contact the Project Team at loud@bcpsqc.ca



### Disclosures

- \* Dr. Stoll
  - \* Worked for the Medical Arts Research Group (no studies or payments for addiction work)

3

- \* Works for Martin Street Outreach Centre
- \* Christine Rutherford, Andrew Kerr
  - \* Interior Health employees

## Objectives

### Learn about how Penticton Regional Hospital has:

- \* Identified the need to develop a Pre-Printed Order Set (PPO)
- \* Engaged local physicians
- \* Created the PPO
- \* Supported the education of physicians and staff

## Increasing OD activity

NEWS'

Penticton averaging a drug overdose per day, prompting renewed calls for overdose prevention site

Shelby Thom 2019-11-18

FEATURED

Valley hits a grim milestone in overdose crisis

RON SEYMOUR Oct 21, 2020

#### Overdoses spike in South Okanagan

Interior Health warns that a drug called purple down may be connected

Nov. 5, 2020 12:00 a.m. / NEWS

## Interior Health issues overdose, fentanyl alert for Penticton


# Fentanyl contaminated stimulants a possible factor in Penticton's April overdose spike: Interior Health

'We have two public health emergencies going on at the same time,' said Dr. Karin Goodison.

May. 12, 2020 12:00 a.m. / NEWS




## Penticton community OD epidemiology






### Interior Health OD Death Chart Review

- \* Reviewed charts of 270 people who died from overdose
- \* Note: Preliminary result, further analysis being completed





## PRH Emergency Department





## Physician Engagement


@PAVEGRANLUND.COM SESAME STREET 2.0 TODAY'S LETTER! OPIOIDS! IS FOR..

## Polling Question


- \* Does your facility have an order set in place?
  - \* YES Regional Health Authority PPO
  - \* YES local local hospital PPO
  - \* NO but informal pathway in place (ie: phone a friend)
  - \* NO no local pathway or process.

## PPO development process

#### Phase 1: IDENTIFICATION & INITIATION



- Identify an opportunity to improve the quality of care for patients by implementing a PPO.
- 2. Check to see if a similar PPO already exists.
- Identify members of a PPO development team and a Lead Developer
- Notify P&T Secretariat (if Health Authority wide)



#### Phase 5: REVIEW / EVALUATION

- The Lead Developer/Implementation Lead will be responsible for coordinating with stakeholders any required evaluation of the PPO.
- Pre-printed orders require an annual review. (Medical Staff Rules for the Interior Health Authority. 6.1.9 May 27, 2014)
- All revisions will be processed and archived through Document Services.



#### Phase 4: IMPLEMENTATION

- Complete Lead
   Developer/Implementation Lead responsibilities.
- 2. Execute Implementation Plan.



- Assemble your team including a pharmacist where applicable.
- Create draft tool following the <u>PPO</u> template.
- Consult stakeholders, including physicians, for feedback.
- Complete revisions.
- 8. Develop Implementation Plan.



#### Phase 3: APPROVAL / ENDORSEMENT

Compile the following for submission to IH P&T


- 1. P&T Agenda Submission Request
- 2. Summary of changes (if a revision)
- Draft pre-printed order
- Development Team, Stakeholders, Feedback, References Summary
- Implementation Plan
  - Consider risk mitigation strategy for operational impact.





## PPO process

Penticton Regional Hospital Local PPO Development / Revision Process



### PPO committee

### **Core Group:**

- \* ED physicians
- \* ED Manager and Director
- \* MHSU Manager and Director
- \* Pharmacy Practice Lead
- \* MHSU Network Practice Lead

### **Ad-hoc participants:**

- \* Addictions Medicine Lead
- \* Medical Health Officer



#### ADULT BUPRENORPHINE-NALOXONE INDUCTION, STABILIZATION AND DISCHARGE ORDERS

Penticton Regional Hospital

Weight (kg)

Bulleted orders are initiated by default, unless crossed out and initialed by the physician/prescriber. Boxed orders ( ) require physician/prescriber check mark ( ) to be initiated.

Indications: This protocol is intended for adult patients (18 years or older) with opioid use disorder who are able to provide informed consent. Patients must be in moderate to severe opioid withdrawal evidenced by Clinical Opiate Withdrawal (COW) Scale greater than or equal to 16 with last immediate release opioid use greater than or equal to 12 hours \*\*OR\*\* last extended / controlled release opioid use greater than or equal to 24 hours.

Contraindications: This protocol should NOT be used for patients with an allergy to buprenorphine or naloxone, severe liver dysfunction (liver enzymes greater than 3 times the upper limit of normal), severe respiratory distress, acute alcohol intoxication or withdrawal, decreased level of consciousness, pregnancy, current methadone or prescribed long acting opioid use. There is a relative contraindication to prescribe benzodiazepines while receiving Buprenophine-Naloxone.


\*\*Physician to complete the Buprenophine-Naloxone Treatment Agreement and Consent Form (#822088)\*\*

14



## PPO algorithm

PHASE 1 – INDUCTION DAY 1 Medication Administration Algorithm






## Discharge Process

- \* Referral to Martin Street Outreach Centre
- \* Prescription given to the patient daily dose on discharge prescription is equal to last daily dose received in hospital
- \* Monday to Friday (0800-1600) an appointment would be booked for the patient and the discharge prescription written to cover them until their appt
- \* After hours, weekends, and holidays the referral is faxed and the patient is given a prescription for a 5 day supply (to allow enough time to establish a follow up appt)
- \* Patient receives a Naloxone kit and training

## Sample Rx



#### 1. DRUG NAME & STRENGTH

Write "buprenorphine/naloxone" and daily dose in milligrams (e.g., 16mg/4mg)

#### 2. QUANTITY

Write the total prescribed dose from start to stop date of the <u>buprenorphine component only</u> in milligrams (mg), in both alpha and numeric format

For example, for a 7-day prescription of 16mg/4mg buprenorphine/naloxone per day, "Quantity" equals: Zdays x 16mg/day = 112mg, and is written both as "112 mg" and "one hundred twelve mg"

#### 3. DIRECTIONS FOR USE

Include the following:

- Daily dose of <u>buprenorphine only</u> in milligrams (mg)
- Sublingual mode of administration (abbreviated SL)
- Once-daily administration
- Prescription start and stop dates (inclusive)
- Total number of days of administration
- Specify if doses are prescribed as DWI or carry
   If witnessed, write "Daily dispense, witnessed ingestion" (preferred) or "DWI"
- If carry doses are prescribed:
  - Write out schedule for DWI and carry doses
  - Request blister- or compliance-package
  - Witnessed ingestion of first dose must be requested

For example, for a 28-day prescription of 16mg/4mg buprenorphine/naloxone per day, dispensed weekly: Take 16mg SL daily

DWI first dose, carries for 6 days in blister pkg Rx: Feb 3 – Mar 2 inclusive (total 28 days)

#### Prescribing reminders:

- · Consider discontinuing or decreasing the dose of all benzodiazepines
- Include the start and end dates for the prescription
- Write "Daily witnessed ingestion with closed day carries"
- Daily dose on discharge prescription is equal to the last daily dose received in hospital
- Quantity determined by patient's follow up appointment at Martin Street Outreach Centre



## Physician Education & Support

- \* Physicians:
  - \* IH funding for physicians to complete POATSP
  - \* Local Champion Dr. Stoll

## Nursing Education



- \* Video presentation of content
- \* Discussion board for nurses asking things like:
  - \* Talk about common myths or misperceptions of people who use substances you've encountered.
  - \* What are some strategies to address stigma
  - \* What can you do to increase cultural safety for indigenous people when they come to your department?
  - \* What are some common challenges that staff have about treating people who use substances in an acute setting?
  - \* What can I do to take care of myself and my colleagues?

## Implementation Plan

- \* Communication with departments and physicians
- \* Build order set in Meditech EMR
- \* Go-Live date:
  - \* Info booth with giveaways / draws
- \* Regional PPO being proposed



### **Action Period 3:**

### People and Provider Centered Care

### **Learning Session 3:**

Tuesday, December 1 @12-1pm Reija Jean & UBC EQUIP Team

#### **Coaching Call 1:**

Wednesday, December 9 @ 3-4pm Sarah Levine & Co-presenters

#### **Coaching Call 2:**

Tuesday, December 15 @ 2-3pm Reija Jean & Mona Kwong

